Institutional Ownership
Alnylam Pharmaceuticals Inc
CUSIP 02043QAB3NOTE 1.000% 9/1ALNYQ1 2026
Latest EPS (Diluted)
$1.21
Q2 2026 · Jun 30, 2026
Latest Revenue
$1.29B
Reported quarter
Latest Net Income
$164.49M
Reported quarter
Quarters on Record
12
From SEC XBRL filings
Quarterly Earnings
EPS, revenue & net income · SEC XBRL (10-Q / 10-K)
| Period | Quarter | EPS (Basic) | EPS (Diluted) | Revenue | Net Income | Form |
|---|---|---|---|---|---|---|
| Jun 30, 2026 | Q2 2026 | $1.23 | $1.21 | $1.29B | $164.49M | 10-Q |
| Mar 31, 2026 | Q1 2026 | — | — | — | $205.99M | 10-Q |
| Sep 30, 2025 | Q3 2025 | $1.91 | $1.84 | $1.25B | $251.08M | 10-Q |
| Jun 30, 2025 | Q2 2025 | $-0.55 | $-0.55 | $773.69M | -$72.23M | 10-Q |
| Mar 31, 2025 | Q1 2025 | $-0.14 | $-0.14 | $594.19M | -$18.25M | 10-K |
| Sep 30, 2024 | Q3 2024 | $-0.87 | $-0.87 | $500.92M | -$111.57M | 10-Q |
| Jun 30, 2024 | Q2 2024 | $-0.13 | $-0.13 | $659.83M | -$16.89M | 10-Q |
| Mar 31, 2024 | Q1 2024 | $-0.52 | $-0.52 | $494.33M | -$65.94M | 10-Q |
| Sep 30, 2023 | Q3 2023 | $1.18 | $1.15 | $750.53M | $147.75M | 10-Q |
| Jun 30, 2023 | Q2 2023 | $-2.21 | $-2.21 | $318.75M | -$276.02M | 10-Q |
| Mar 31, 2023 | Q1 2023 | $-1.40 | $-1.40 | $319.29M | -$174.10M | 10-Q |
| Sep 30, 2022 | Q3 2022 | $-3.32 | $-3.32 | $264.31M | -$405.92M | 10-Q |